Dynavax Technologies Corporation (LON:0IDA)

Market Cap	1.34B
Revenue (ttm)	245.88M
Net Income (ttm)	-32.29M
Shares Out	n/a
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	20.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,566
Average Volume	1,366
Open	15.40
Previous Close	11.11
Day's Range	15.20 - 15.73
52-Week Range	9.28 - 15.73
Beta	0.89
RSI	88.72
Earnings Date	Feb 20, 2026

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1996
• Employees: 405
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IDA

Financial Performance

Financial numbers in USD